Cetuximab + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuralgia
Conditions
Neuralgia, Complex Regional Pain Syndromes
Trial Timeline
Oct 1, 2015 → Oct 1, 2016
NCT ID
NCT02490436About Cetuximab + Placebo
Cetuximab + Placebo is a phase 2 stage product being developed by Merck for Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT02490436. Target conditions include Neuralgia, Complex Regional Pain Syndromes.
What happened to similar drugs?
8 of 18 similar drugs in Neuralgia were approved
Approved (8) Terminated (3) Active (8)
🔄Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02490436 | Phase 2 | Completed |
Competing Products
20 competing products in Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + DS-5565 | Daiichi Sankyo | Pre-clinical | 26 |
| QUTENZA | Astellas Pharma | Approved | 43 |
| ASP8477 + Placebo | Astellas Pharma | Phase 2 | 35 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 35 |
| E2007 | Eisai | Phase 2/3 | 38 |
| KHK6188 + Placebo | Kyowa Kirin | Phase 2 | 35 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 39 |
| Galcanezumab | Eli Lilly | Approved | 43 |
| Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine | AbbVie | Phase 2 | 35 |
| MK-8291 + Placebo | Merck | Phase 1 | 29 |
| Etoricoxib + Placebo | Merck | Approved | 39 |
| ADL5747 + Placebo + Pregabalin | Merck | Phase 2 | 27 |
| MK0759 | Merck | Phase 2 | 27 |
| MK0686 | Merck | Phase 2 | 27 |
| Comparator: pregabalin + Comparator: Placebo (unspecified) | Merck | Phase 1 | 29 |
| EMA401 + Placebo | Novartis | Phase 2 | 27 |
| pregabalin | Pfizer | Approved | 43 |
| Lyrica (pregabalin) + Placebo | Pfizer | Approved | 43 |
| 2-weeks placebo then gabapentin + 1-week placebo then gabapentin | Pfizer | Pre-clinical | 26 |